文献速递哮喘

体重调整静脉瑞利珠单抗用于固定剂量皮下美泊利单抗应答不足的重度哮喘

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

这项单盲安慰剂对照序贯试验纳入10例口服泼尼松依赖且痰嗜酸粒细胞>3%、血嗜酸粒细胞>300 cells/μl的重度哮喘患者,既往接受100 mg皮下美泊利单抗至少1年。结果显示,体重调整静脉瑞利珠单抗3.0 mg/kg每4周一次较安慰剂显著降低痰嗜酸粒细胞91.2%、血嗜酸粒细胞87.4%,并改善FEV1和哮喘控制问卷评分;痰嗜酸粒细胞降幅优于美泊利单抗。

要点

  • 对固定剂量皮下美泊利单抗应答不足的泼尼松依赖重度哮喘,可考虑体重调整静脉瑞利珠单抗。
  • 瑞利珠单抗较安慰剂显著降低痰和血嗜酸粒细胞,并改善FEV1与哮喘控制。
  • 痰IL-5和抗嗜酸粒细胞过氧化物酶IgG变化可能预测抗IL-5治疗反应。

核心结论

  • 体重调整静脉瑞利珠单抗在减轻泼尼松依赖哮喘患者气道嗜酸粒细胞方面优于固定剂量皮下美泊利单抗,并伴随哮喘控制改善。

研究设计与样本

  • 单盲、安慰剂对照序贯试验,纳入10例泼尼松依赖哮喘患者,既往接受100 mg皮下美泊利单抗每4周一次至少1年。
  • 患者先接受两次安慰剂输注每4周一次,随后接受四次3.0 mg/kg瑞利珠单抗每4周一次。
  • 主要结局为痰和血嗜酸粒细胞减少。

主要发现

  • 与安慰剂相比,静脉瑞利珠单抗使痰嗜酸粒细胞减少91.2%(P=0.002),血嗜酸粒细胞减少87.4%(P=0.004),痰嗜酸粒细胞过氧化物酶减少65.5%(P=0.03)。
  • 局部和全身嗜酸粒细胞减少与FEV1(P=0.004)和哮喘控制问卷五问题版评分(P=0.006)的统计学显著改善相关。
  • 痰嗜酸粒细胞百分比降幅瑞利珠单抗组(42.7%)大于美泊利单抗组(5.0%),且与哮喘控制问卷更大改善相关(P=0.01;协方差分析,调整基线泼尼松)。
  • 抗IL-5治疗后痰IL-5和抗嗜酸粒细胞过氧化物酶IgG变化是反应的预测因素。

临床怎么用

  • 对于固定剂量皮下美泊利单抗治疗后痰嗜酸粒细胞仍控制不佳的泼尼松依赖重度哮喘患者,体重调整静脉瑞利珠单抗可能更有效减轻气道嗜酸粒细胞炎症并改善哮喘控制。

局限性

  • 样本量小(10例),为单盲序贯设计,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Clinical benefits of fixed-dose 100-mg subcutaneous (SC) mepolizumab in prednisone-dependent patients are modest when sputum eosinophilia is not adequately controlled. OBJECTIVES: This study compared treatment response of weight-adjusted intravenous (IV) reslizumab in patients previously treated with 100-mg SC mepolizumab. METHODS: Ten prednisone-dependent patients with asthma (sputum eosinophils >3% and blood eosinophils >300 cells/μl), who had previously received mepolizumab (100 mg SC dosed every 4 wk [Q4W]) for at least 1 year, received two infusions of placebo (Q4W) followed by four infusions of 3.0 mg/kg reslizumab Q4W in a single-blind, placebo-controlled sequential trial. Primary outcomes were reduction of eosinophils in sputum and blood. Additional outcomes included FEV1, asthma control questionnaire, eosinophil peroxidase, IL-5, sputum and blood innate lymphoid cells group 2, eosinophil progenitor cells, and autoimmune responses. MEASUREMENTS AND MAIN RESULTS: IV reslizumab attenuated sputum eosinophils by 91.2% (P = 0.002), blood eosinophil counts by 87.4% (P = 0.004), and sputum eosinophil peroxidase levels by 65.5% (P = 0.03) compared with placebo. Attenuation of both local and systemic eosinophilia was associated with statistically significant improvements in FEV1 (P = 0.004) and asthma control questionnaire five-question instrument scores (P = 0.006). Decrease in percent sputum eosinophil was greater with reslizumab (by 42.7%) compared with mepolizumab (by 5.0%) and this was associated with greater improvement in asthma control questionnaire (P = 0.01; analysis of covariance of Δ between before and after treatment, mepolizumab vs. reslizumab, adjusted for baseline prednisone). Changes in sputum IL-5 and anti-eosinophil peroxidase IgG after anti-IL-5 therapy were predictors of response. CONCLUSIONS: Weight-adjusted IV reslizumab was superior to fixed-dose SC mepolizumab in attenuating airway eosinophilia in prednisone-dependent patients with asthma, with associated improvement in asthma control. Clinical trial registered with www.clinicaltrials.gov (NCT 02559791).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab. Am J Respir Crit Care Med. 2018. PMID: 28915080. doi:10.1164/rccm.201707-1323OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。